Citius Pharmaceuticals is trading 11.49% down at $0.69 after profit-taking and consolidation following the LYMPHIR-driven rally.
- Shares rose 25.45% to $0.78 on August 5 after Citius Oncology reported expanding institutional orders, formulary progress, and commercial-launch momentum for LYMPHIR.
- The decline appears to reflect investors locking in gains rather than a newly reported negative company event.
- Broader healthcare sentiment remains positive, making sector weakness an unlikely primary driver.